NasdaqGM - Delayed Quote • USD
CorMedix Inc. (CRMD)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:48 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.28 | -0.26 | -0.74 | -0.09 |
| Low Estimate | -0.32 | -0.28 | -1.09 | -0.67 |
| High Estimate | -0.25 | -0.22 | -0.26 | 0.55 |
| Year Ago EPS | -0.24 | -0.25 | -0.91 | -0.74 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -- | 1.67M | 25.16M | 81.93M |
| Low Estimate | -- | 200k | 14.6M | 66.95M |
| High Estimate | -- | 3.7M | 46.33M | 105.75M |
| Year Ago Sales | -- | -- | -- | 25.16M |
| Sales Growth (year/est) | -- | -- | -- | 225.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.2 | -0.24 | -0.21 | -0.2 |
| EPS Actual | -0.24 | -0.25 | -0.17 | -0.26 |
| Difference | -0.04 | -0.01 | 0.04 | -0.06 |
| Surprise % | -20.00% | -4.20% | 19.00% | -30.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.28 | -0.26 | -0.74 | -0.09 |
| 7 Days Ago | -0.28 | -0.26 | -0.74 | -0.09 |
| 30 Days Ago | -0.28 | -0.26 | -0.74 | -0.09 |
| 60 Days Ago | -0.26 | -0.28 | -0.76 | -0.23 |
| 90 Days Ago | -0.2 | -0.22 | -0.73 | -0.23 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CRMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -16.70% | -- | -- | 1.60% |
| Next Qtr. | -4.00% | -- | -- | 10.50% |
| Current Year | 18.70% | -- | -- | 5.20% |
| Next Year | 87.80% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 4/9/2024 |
| Reiterates | Needham: Buy to Buy | 4/9/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 3/13/2024 |
| Maintains | Needham: Buy to Buy | 3/12/2024 |
| Maintains | Truist Securities: Buy to Buy | 1/31/2024 |
| Maintains | Needham: Buy to Buy | 11/15/2023 |
Related Tickers
TCRT Alaunos Therapeutics, Inc.
1.1200
-8.20%
RZLT Rezolute, Inc.
3.4300
+3.94%
VNDA Vanda Pharmaceuticals Inc.
5.11
+2.82%
CKPT Checkpoint Therapeutics, Inc.
1.4600
-8.75%
AKBA Akebia Therapeutics, Inc.
1.3600
-2.16%
CADL Candel Therapeutics, Inc.
5.17
-5.31%
ELYM Eliem Therapeutics, Inc.
3.8500
-7.89%
ATNM Actinium Pharmaceuticals, Inc.
6.85
+2.70%
ACRV Acrivon Therapeutics, Inc.
9.39
-10.91%
ALDX Aldeyra Therapeutics, Inc.
3.8600
-3.02%